Prophase Labs Inc (PRPH) |
|
6.76 0.21 (3.21%)
|
03-07 04:02 |
|
Open: |
6.6 |
Pre. Close: |
6.55 |
|
High:
|
6.83 |
Low:
|
5.9299 |
|
Volume:
|
127,888 |
Market Cap:
|
102M |
|
|
|
|
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer consumer healthcare products and dietary supplements. The company is headquartered in Doylestown, Pennsylvania and currently employs 54 full-time employees. The firm is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The firm's products include TK Supplements and ORXx Complete. TK Supplements consists of LEGENDZ XL, a male sexual enhancement; TRIPLE EDGE XL, a daily energy and stamina booster, and SUPER PROSTAFLOW plus, a supplement to support prostate and urinary health. The firm's OTC offerings include the ORXx cough/cold drops. Its consumer health customers include national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.833 - 6.874 |
6.874 - 6.914 |
|
Low:
|
5.844 - 5.887 |
5.887 - 5.928 |
|
Close:
|
6.686 - 6.757 |
6.757 - 6.826 |
|
Technical analysis |
as of: 2021-03-05 5:12:11 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 10.95  One year: 13.43 |
| Support: |
Support1: 5.93 Support2: 4.93 |
| Resistance: |
Resistance1: 9.37 Resistance2: 11.50 |
| Pivot: |
8.42 |
| Moving Average: |
MA(5): 7.20 MA(20): 9.01
MA(100): 9.57 MA(250): 5.14 |
| MACD: |
MACD(12,26): -1.11 Signal(9): -0.89 |
| Stochastic oscillator: |
%K(14,3): 6.51 %D(3): 7.02 |
| RSI: |
RSI(14): 30.16 |
| 52-week: |
High: 16.04 Low: 1.20 Change(%): 236.3 |
| Average Vol(K): |
3-Month: 19691 10-Days: 16625 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.PRPH has closed above bottom band by 17.6%. Bollinger Bands are 16.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 24 Feb 2021
Analyst: All Systems Are Go for Testing, Testing and More Testing - Streetwise Reports
Wed, 17 Feb 2021
With Pivot To COVID-19 Testing, ProPhase Labs Could Greatly Reward Shareholders - Seeking Alpha
Wed, 17 Feb 2021
Analysts Expect ProPhase Labs, Inc. (NASDAQ:PRPH) To Breakeven Soon - Yahoo Finance
Tue, 16 Feb 2021
ProPhase Labs presents at Proactive"s One2One virtual investor forum - Proactive Investors USA & Canada
Thu, 11 Feb 2021
ProPhase Labs: Meet the team that"s looking to revolutionize coronavirus testing - Proactive Investors USA & Canada
Tue, 09 Feb 2021
ProPhase Labs debuts single saliva test for COVID, flu - Mass Device
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers General Specialty & Generic |
| Shares Out. (M) |
15 |
| Shares Float (M) |
9 |
|
% Held by Insiders
|
24.22 |
|
% Held by Institutions
|
4.17 |
|
Shares Short (K)
|
86 |
|
Shares Short P. Month (K)
|
127 |
Stock Financials |
|
EPS
|
-0.140 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
0.930 |
|
Profit Margin
|
-12.92 |
|
Operating Margin
|
-14.30 |
|
Return on Assets (ttm)
|
-5.8 |
|
Return on Equity (ttm)
|
-13.8 |
|
Qtrly Rev. Growth
|
38.8 |
|
Gross Profit (p.s.)
|
0.173 |
|
Sales Per Share
|
0.824 |
|
EBITDA (p.s.)
|
-0.095 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
4 |
|
Levered Free Cash Flow (M)
|
4 |
Stock Valuations |
|
PE Ratio
|
-48.29 |
|
PEG Ratio
|
|
|
Price to Book value
|
7.27 |
|
Price to Sales
|
8.20 |
|
Price to Cash Flow
|
27.31 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2019-12-11 |
|
Ex-Dividend Date
|
2019-12-01 |
|
7 Binary Options
|
|
Your Ad Here
|
|
